search

Active clinical trials for "Ischemia"

Results 811-820 of 2694

THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention...

Acute Ischaemic StrokeTransient Ischaemic Attack

Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events

Completed34 enrollment criteria

Ripple Mapping Guided Ablation of Ischaemic Ventricular Tachycardia.

Ventricular TachycardiaIschemic Heart Disease

The Ripple VT-1 Study is a prospective clinical trial that aims to investigate if catheter ablation of ventricular tachycardia in patients with ischaemic heart disease can be effectively performed using Ripple Mapping.

Completed19 enrollment criteria

Efficacy Argatroban in Ischemic Stroke With Early Deterioration (EASE)

Acute Progressive Ischemic Stroke

Acute ischemic stroke (AIS) has the characteristics of high morbidity, high mortality, high disability rate and high recurrence rate. Progressive cerebral infarction (PIS) is a subtype of AIS, accounting for 10% - 40%. Because of the gradual aggravation of neurological deficit symptoms, it has a higher rate of disability and death, which brings heavy mental and economic burden to families, society and the country. The progress of acute cerebral infarction is generally within 6 hours to 1 week after the onset of the disease. At present, it is considered that thrombus prolongation is one of the important pathogenesis of PIS. Heparin can reduce the incidence of post-stroke embolism, but its benefits are offset by the risk of hemorrhage due to the high risk of hemorrhage. The 2013AHA guidelines in the United States do not recommend it as a routine anticoagulant therapy. Therefore, reducing the risk of bleeding is the key to the anticoagulation therapy of PIS. Argatroban is a new thrombin inhibitor. Its mechanism of action is to bind and inactivate thrombin (factor Ⅱ a) directly.Compared with traditional anticoagulants, argatroban not only has the advantages of good anticoagulant effect and rapid onset, but also has high safety. Therefore, this study aims to verify the clinical efficacy of Argatroban in the treatment of PIS in a large population. In this study, 628 patients are expected to be enrolled into the study group. The experimental group and the control group are selected by dynamic random method. Both groups are given standard medical treatment, including routine antiplatelet, blood pressure control, statins to stabilize plaque, etc. The control group is only given standard medical treatment. In the experimental group, Argatroban is used on the basis of standard medical treatment. Both groups are treated for 7 days, and the second-class prevention standard medical treatment is given from the 8th to the 90th day. The main outcome measure is the good prognosis rate at the third month after PIS. The good prognosis was defined as the modified Rankin Scale (mRS) ≤ 3.

Completed14 enrollment criteria

INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE

Ischemic StrokeIndobufen1 more

China has the largest burden of cerebrovascular disease in the world. About 60% to 80% of which are ischemic stroke. In recent years, stroke has replaced heart disease and tumor diseases as the first cause of death and disability in adult population. The primary purpose of this study is to evaluate the efficacy of indobufen treatment in reducing the risk of a 3-month new stroke (any type of stroke, including ischemic stroke and hemorrhagic stroke) for patients with moderate/severe ischemic stroke is not inferior to aspirin therapy.

Completed28 enrollment criteria

Investigating the Safety and Efficacy of the Treatment With Luminor DCB and Angiolite DES of iVascular...

Critical Limb Ischemia

This study aims to evaluate the 12 month outcome of the mono- or combination therapy with iVascular Luminor DCB and Angiolite DES for treatment of TASC C and TASC D long tibial occlusive disease, presenting with critical limb ischemia.

Completed39 enrollment criteria

Investigating the Safety and Efficacy of the Treatment With the Selution Sirolimus Coated Balloon...

Critical Limb Ischemia

The objective of this clinical investigation is to evaluate the 6-month outcome of the Selution Sirolimus-coated Balloon for the treatment of long tibial occlusive disease (TASC C and D) in patients with Critical Limb Ischemia (CLI)

Completed40 enrollment criteria

Remote Limb Ischemic Conditioning to Enhance Learning and Muscle Strength in Healthy Young Adults...

HealthyYoung Adults

The purpose of this research study is to determine if remote limb ischemic conditioning (RLIC) can enhance learning of a motor (balance) and an ecologically valid, complex cognitive-motor (driving) task, and increase skeletal muscle strength in neurologically-intact young adults.

Completed12 enrollment criteria

Effect of Number of Remote Limb Ischemic Conditioning Cycles on Learning Enhancement

HealthyYoung Adults

The purpose of this research study is to determine the effect of number of remote limb ischemic conditioning (RLIC) cycles on enhancing learning in neurologically intact young adults.

Completed10 enrollment criteria

The Efficacy and Safety of Sofadil for Injection in the Treatment of Acute Ischemic Stroke

Acute Ischemic Stroke

To evaluate the efficacy and safety of sofadil injection in the treatment of acute ischemic stroke

Completed31 enrollment criteria

Blood Pressure Variability and Ischemic Stroke Outcome

Acute Ischemic StrokeBlood Pressure Variability

The goal of this observational study is to evaluate the role of blood pressure (BPV) variability in patients suffering from acute ischemic stroke. The main questions it aims to answer are: To determine the association of BPV with functional/cognitive outcome after ischemic stroke. To determine a pathophysiologic mechanism of BPV's deleterious effect on functional outcome. To evaluate potential treatment targets to pharmacologically reduce BPV after ischemic stroke.

Not yet recruiting8 enrollment criteria
1...818283...270

Need Help? Contact our team!


We'll reach out to this number within 24 hrs